-
EP4210742
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4210742
| EP4210742 - BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 01.11.2024 Database last updated on 09.04.2026 | |
| Former | Request for examination was made Status updated on 16.06.2023 | ||
| Former | The international publication has been made Status updated on 23.03.2022 | ||
| Former | unknown Status updated on 07.10.2021 | Most recent event Tooltip | 02.10.2025 | New entry: Renewal fee paid | Applicant(s) | For all designated states Genmab A/S Carl Jacobsens Vej 30 2500 Valby / DK | [2023/42] |
| Former [2023/29] | For all designated states Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V / DK | Inventor(s) | 01 /
ELLIOTT, Brian Plainsboro, New Jersey 08536 / US | 02 /
AHMADI, Tahamtan Plainsboro, New Jersey 08536 / US | 03 /
CHIU, Christopher Plainsboro, New Jersey 08536 / US | 04 /
BREIJ, Esther C. W. 3584 CT Utrecht / NL | 05 /
HIEMSTRA, Ida 3584 CT Utrecht / NL | 06 /
JURE-KUNKEL, Maria N. Plainsboro, New Jersey 08536 / US | [2023/29] | Representative(s) | Genmab A/S Carl Jacobsens Vej 30 2500 Valby / DK | [N/P] | Application number, filing date | 21777653.3 | 10.09.2021 | [2023/29] | WO2021EP75017 | Priority number, date | US202063076740P | 10.09.2020 Original published format: US 202063076740 P | [2023/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022053655 | Date: | 17.03.2022 | Language: | EN | [2022/11] | Type: | A1 Application with search report | No.: | EP4210742 | Date: | 19.07.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.03.2022 takes the place of the publication of the European patent application. | [2023/29] | Search report(s) | International search report - published on: | EP | 17.03.2022 | Classification | IPC: | A61K39/395, A61P35/02, C07K16/28, A61K39/00 | [2023/29] | CPC: |
C07K16/2887 (EP,IL,KR,US);
A61K39/395 (EP,IL,KR);
A61K31/454 (IL,KR,US);
A61P35/00 (US);
A61P35/02 (EP,IL,KR);
C07K16/2809 (EP,IL,KR,US);
C07K16/468 (US);
A61K2039/507 (EP,IL,KR);
A61K2039/545 (KR);
A61K2300/00 (KR);
C07K2317/24 (IL,US);
C07K2317/31 (EP,IL,KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/29] | Extension states | BA | 04.04.2023 | ME | 04.04.2023 | Validation states | KH | 04.04.2023 | MA | 04.04.2023 | MD | 04.04.2023 | TN | 04.04.2023 | Title | German: | BISPEZIFISCHER ANTIKÖRPER GEGEN CD3 UND CD20 IN EINER KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON FOLLIKELLYMPHOM | [2023/29] | English: | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA | [2023/29] | French: | ANTICORPS BISPÉCIFIQUE CONTRE CD3 ET CD20 EN POLYTHÉRAPIE POUR LE TRAITEMENT D'UN LYMPHOME FOLLICULAIRE | [2023/29] | Entry into regional phase | 04.04.2023 | National basic fee paid | 04.04.2023 | Designation fee(s) paid | 04.04.2023 | Examination fee paid | Examination procedure | 04.04.2023 | Examination requested [2023/29] | 04.04.2023 | Date on which the examining division has become responsible | 01.11.2023 | Amendment by applicant (claims and/or description) | 06.11.2024 | Despatch of a communication from the examining division (Time limit: M06) | 06.05.2025 | Reply to a communication from the examining division | Fees paid | Renewal fee | 24.08.2023 | Renewal fee patent year 03 | 30.09.2024 | Renewal fee patent year 04 | 30.09.2025 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A] WO2016110576 (GENMAB AS et al.) | [A] MORSCHHAUSER FRANCK ET AL: "Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 379, no. 10, 6 September 2018 (2018-09-06), US, pages 934 - 947, XP055855089, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1805104 DOI: http://dx.doi.org/10.1056/NEJMoa1805104 | [AD] PATRICK J. ENGELBERTS ET AL: "DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing", EBIOMEDICINE, vol. 52, 1 February 2020 (2020-02-01), NL, pages 102625, XP055762370, ISSN: 2352-3964, DOI: 10.1016/j.ebiom.2019.102625 DOI: http://dx.doi.org/10.1016/j.ebiom.2019.102625 | [AD] VAN DER HORST HILMA J ET AL: "Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo, Irrespective of Prior Treatment with CD20 Monoclonal Antibodies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 134, 13 November 2019 (2019-11-13), pages 4066, XP086675260, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2019-125765 DOI: http://dx.doi.org/10.1182/blood-2019-125765 | Examination | CELGENE: "BEGINNING YOUR R2 TREATMENT JOURNEY A CHEMOTHERAPY-FREE TREATMENT COMBINATION FOR PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR OR MARGINAL ZONE LYMPHOMA", 1 January 2019 (2019-01-01), pages 1 - 11, XP093219017, Retrieved from the Internet | SALLES GILLES: "How do I sequence therapy for follicular lymphoma?", AMERICAN SOCIETY OF HEMATOLOGY, vol. 2020, no. 1, 4 December 2020 (2020-12-04), US, pages 287 - 294, XP093219032, ISSN: 1520-4391, DOI: 10.1182/hematology.2020000156 DOI: http://dx.doi.org/10.1182/hematology.2020000156 | LINTON KIM M. ET AL: "EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R 2 ) vs chemoimmunotherapy or R 2 in previously untreated follicular lymphoma.", JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16_suppl, 1 June 2024 (2024-06-01), pages TPS7084 - TPS7084, XP093219107, ISSN: 0732-183X, DOI: 10.1200/JCO.2024.42.16_suppl.TPS7084 [P] DOI: http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.TPS7084 | HENRICKS LINDA M ET AL: "The use of combinations of monoclonal antibodies in clinical oncology", CANCER TREATMENT REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 41, no. 10, 30 October 2015 (2015-10-30), pages 859 - 867, XP029315379, ISSN: 0305-7372, DOI: 10.1016/J.CTRV.2015.10.008 [T] DOI: http://dx.doi.org/10.1016/j.ctrv.2015.10.008 | by applicant | WO2007059782 | WO2016110576 | WO9222653 | EP0629240 | US5736137 | WO2019155008 | WO2015001085 | WO2004035607 | WO9850431 | WO2011117329 | EP1870459 | WO2009089004 | US15513310 | WO2010129304 | WO2011131746 | WO2013060867 | RELANDER ET AL., J CLIN ONCOL, vol. 28, 2010, pages 2902 - 13 | WAGNER-JOHNSTON ET AL., BLOOD, vol. 126, 2015, pages 851 - 7 | HIDDEMANN ET AL., BLOOD, vol. 106, 2005, pages 3725 - 32 | RUMMEL ET AL., LANCET, vol. 381, 2013, pages 1203 - 10 | JURINOVIC ET AL., BIOL BLOOD MARROW TRANSPLANT, vol. 24, 2018, pages 1172 - 71 | LEONARD ET AL., J CLIN ONCOL, vol. 37, 2019, pages 1188 - 99 | SALLES ET AL., HAEMATOLOGICA, 2017, pages el56 | WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 46 | CHOTHIALESK, J MOL BIOI, vol. 196, 1987, pages 901 - 17 | BROCHET X., NUCL ACIDS RES, vol. 36, 2008, pages W503 - 508 | LEFRANC MP., NUCL ACIDS RES, vol. 27, 1999, pages 209 - 12, Retrieved from the Internet | EDELMAN ET AL., PNAS, vol. 63, 1969, pages 78 - 85 | KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991 | HOLT ET AL., TRENDS BIOTECHNOL, vol. 21, 2003, pages 484 - 90 | REVETS ET AL., EXPERT OPIN BIOL THER, vol. 5, 2005, pages 111 - 24 | BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 26 | HUSTON ET AL., PNAS, vol. 85, 1988, pages 5879 - 83 | E. MEYERSW. MILLER, COMPUT. APPL. BIOSCI, vol. 4, 1988, pages 11 - 17 | NEEDLEMANWUNSCH, JMOL BIOL, vol. 48, 1970, pages 444 - 453 | KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 | MENDEZ ET AL., NAT GENET, vol. 15, 1997, pages 146 - 56 | SWERDLOW SHCAMPO EHARRIS NL ET AL.: "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 2017, IARC PRESS | CAS , no. 174722-31-7 | CHEMICAL ABSTRACTS SERVICE, no. 191732-72-6 | BARRINGTON ET AL., J CLIN ONCOL, vol. 32, 2014, pages 3048 - 58 | OKEN ET AL., AM J CLIN ONCOL, vol. 5, no. 6, December 1982 (1982-12-01), pages 649 - 55 | LEE ET AL., BIOL BLOOD MARROW TRANSPLANT, vol. 25, 2019, pages 625 - 638 | HOWARD ET AL., N ENGL J MED, vol. 364, 2011, pages 1844 - 54 | COIFFIER ET AL., J CLIN ONCOL, vol. 26, 2008, pages 2767 - 78 | LEFRANC ET AL., NUCLEIC ACIDS RESEARCH, vol. 27, 1999, pages 209 - 12 | KONTERMANN, DRUG DISCOV TODAY, vol. 20, 2015, pages 838 - 47 | MABS, vol. 4, 2012, pages 182 - 97 | SHIELDS ET AL., JBC, vol. 276, 2001, pages 6591 - 604 | VAN DER HORST ET AL., BLOOD, vol. 134, 2019, pages 4066 | WOLCHOK ET AL., CLIN CANCER RES, vol. 15, 2009, pages 7412 - 20 | CHESON ET AL., BLOOD, vol. 128, 2016, pages 2489 - 96 |